About Daniel Hartley
Daniel Hartley is a pharmacology writer who explains how weight loss medications work at the molecular level — and why that matters for the people taking them. He holds a Master of Science in Pharmacology from Georgetown University, where his thesis research examined GLP-1 receptor signaling pathways and their downstream effects on appetite regulation and glucose homeostasis. Before becoming a writer, Daniel spent four years as a bench scientist in a peptide therapeutics research lab, synthesizing and characterizing GLP-1 receptor agonist analogs. He understands these drugs not as brand names on a prescription pad but as engineered molecules with specific binding affinities, half-lives, and pharmacokinetic profiles — and he writes with that precision.
After leaving the bench, Daniel transitioned into pharmaceutical medical affairs, where he spent three years writing clinical summaries, mechanism-of-action documents, and medical information response letters for cardiometabolic drug programs. He worked across multiple product launches in the GLP-1 and dual GIP/GLP-1 agonist space, giving him a front-row seat to the clinical development pipeline that has since reshaped obesity treatment. It was during this period that he realized the explanatory content reaching patients bore almost no resemblance to the science he was writing internally — the mechanism-of-action sections on consumer health websites were vague, often inaccurate, and almost never cited primary pharmacology literature. He began writing for general audiences to fix that.
At Losing Weight RX, Daniel is the go-to author for pharmacology deep dives. He writes the site's mechanism-of-action explainers, drug interaction guides, and pharmacokinetic breakdowns — the content that answers "how does this drug actually work in my body?" with real science instead of marketing copy. He is a member of the American Society for Pharmacology and Experimental Therapeutics and the Drug Information Association, and he maintains active engagement with published pharmacology literature. His writing is technical but never impenetrable — he believes that patients who understand the pharmacology of their medication are better equipped to use it safely, ask informed questions, and recognize when something isn't right.
Articles by Daniel Hartley
FDA Committee to Review Restricted Peptides in July
June 7, 2026
Topical ABT-263 Speeds Aged Skin Wound Healing
June 6, 2026
Zealand and Roche Share ZUPREME-1 Petrelintide Data
June 5, 2026
FLOW Subgroup Confirms Semaglutide Kidney Protection
June 3, 2026
Roche to Trial CT-388 and Petrelintide Obesity Combo
June 2, 2026
GWAS Identifies Genetic Variants Linked to GLP-1 Response
May 31, 2026
Wegovy Linked to 5x Higher Eye Stroke Risk vs Ozempic
May 30, 2026
FDA Peptide Rules Restrict Sermorelin Access
May 29, 2026